🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Mohammadhadi Bagheri

National Institutes of Health

ORCID: 0000-0002-9273-5359

Also affiliated with Government of the United States of America, National Institutes of Health Clinical Center, Tehran University of Medical Sciences

MedicineComputer ScienceEngineering

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors”.

Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

Journal of Clinical Oncology(2020)10.1200/jco.20.01652

N/A

3.5DataRank · unranked

138 citations

Rosa Nadal, Daniel M. Girardi, Scot A. Niglio, Lisa Ley, Lisa M. Cordes +30 more

Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-0056

N/A

0DataRank · unranked

224 citations

Alexandra S. Zimmer, Michelle R. Padget, Ashley Cimino‐Mathews, Jayakumar R. Nair, Yingmiao Liu +13 more

Ipilimumab challenge/re-challenge in metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors treated with cabozantinib+nivolumab (CaboNivo) or cabozantinib+nivolumab+ipilimumab (CaboNivoIpi).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5039

N/A

0DataRank · unranked

3 citations

Daniel M. Girardi, Amir Mortazavi, Primo N. Lara, Sumanta K. Pal, Biren Saraiya +15 more

Phase I expansion study of cabozantinib plus nivolumab (CaboNivo) in metastatic urothelial carcinoma (mUC) patients (pts) with progressive disease following immune checkpoint inhibitor (ICI) therapy.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5037

N/A

0DataRank · unranked

2 citations

Scot A. Niglio, Amir Mortazavi, Primo Lara, Sumanta K. Pal, Biren Saraiya +15 more

Appendiceal Metastasis From Thymic Carcinoma: An Unusual Presentation of a Rare Cancer

JTO Clinical and Research Reports(2020)10.1016/j.jtocrr.2020.100039

N/A

0DataRank · unranked

0 citations

Osório Lopes Abath Neto, Mohammadhadi Bagheri, Alfred Saleh, Patrick J. Loehrer, Arun Rajan +1 more

A pilot study of volumetric and density tumor analysis of ACC patients treated with vorinostat in a phase II clinical trial

Heliyon(2023)10.1016/j.heliyon.2023.e18680

N/A

0DataRank · unranked

5 citations

Alex P. Toscano, Mohammadhadi Bagheri, Jeffrey Solomon, Laura B. Machado, Patricia LoRusso +4 more

Phase I results of human endogenous retrovirus type-E (HERV-E) TCR transduced T-cells in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.2549

N/A

0DataRank · unranked

5 citations

Stefan Barisic, Gina Scurti, Elena Cherkasova, Long Chen, Kristen Wood +13 more

Automated abnormality classification of chest radiographs using deep convolutional neural networks

npj Digital Medicine(2020)10.1038/s41746-020-0273-z

N/A

0DataRank · unranked

255 citations

Youbao Tang, Yifan Peng, Ke Yan, Mohammadhadi Bagheri, Bernadette Redd +6 more

Final results from a phase 1 trial and expansion cohorts of cabozantinib and nivolumab alone or with ipilimumab for advanced/metastatic genitourinary tumors

Research Square(2023)10.21203/rs.3.rs-2924051/v1

N/A

0DataRank · unranked

0 citations

Scot A. Niglio, Rosa Nadal, Andre R. Kydd, Nicholas I. Simon, Lisa Ley +36 more